Close
Achema middle east
swop processing & packaging

ARTES Biotech to Develop VLP SARS-CoV-2 Vax Candidates

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

7 Most Important Contents in a Trauma Kit

Knowing what to include in a trauma kit is...

New Tariff Announcement by Trump for Pharma, Patented Drugs

The announcement made by President Donald Trump that his...

U.S. Tariff Relief for EU and Japan on Pharmaceuticals

Donald Trump’s new tariffs when it comes to pharmaceutical...

Five key considerations for biotechs outsourcing biologics manufacturing

Outsourcing is now critical for biotech companies aiming to...

ARTES Biotechnology, a biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX and SplitCore.

METAVAX is a platform for the development of vaccines built on enveloped virus-like particle nanostructures (eVLPs) based on the duck Hepatitis B small surface antigen. SplitCore is the technology where capsid virus-like particles (cVLPs) are applied as antigen presentation vehicles without involvement of host lipid membrane structures.

The development approach of ARTES is designed to present domains of the spike protein of SARS-CoV-2 – with or without an antigen derived from the virus´ nucleocapsid protein – on the surface of eVLPs (METAVAX) and cVLPs (SplitCore).

Virus-like particles mimic the conformation of authentic native viruses without being infectious. They consist of one or more structural proteins that have the ability to self-assemble to mimic the structure of real viruses and to present foreign epitopes or complete antigens on their surface. Because of lacking a viral genome, recombinant VLPs are superior to native viruses while at the same time maintaining the same potential to trigger a strong immune response.

In September 2019, ARTES and Australian Burnett Institute published data on the efficient production of malaria vaccine candidates using virus-like particles (eVLP) produced with ARTES’ METAVAX platform presenting malaria transmission-stage antigens, which were capable of inducing transmission-blocking antibodies.

Latest stories

Related stories

7 Most Important Contents in a Trauma Kit

Knowing what to include in a trauma kit is...

New Tariff Announcement by Trump for Pharma, Patented Drugs

The announcement made by President Donald Trump that his...

U.S. Tariff Relief for EU and Japan on Pharmaceuticals

Donald Trump’s new tariffs when it comes to pharmaceutical...

Five key considerations for biotechs outsourcing biologics manufacturing

Outsourcing is now critical for biotech companies aiming to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »